TG Therapeutics

$44.83
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.06 (+2.42%) As of 4:13 PM UTC today

Why Robinhood?

You can buy or sell TGTX and other stocks, options, and ETFs commission-free!

About TGTX

TG Therapeutics, Inc. Common Stock, also called TG Therapeutics, is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. The listed name for TGTX is TG Therapeutics, Inc. Common Stock.

CEO
Michael Sean Weiss
Employees
134
Headquarters
New York, New York
Founded
1993
Market Cap
6.38B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.36M
High Today
$45.34
Low Today
$43.96
Open Price
$44.41
Volume
267.64K
52 Week High
$56.74
52 Week Low
$6.34

TGTX Earnings

-$0.73
-$0.49
-$0.24
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Today, After Hours
Preview Earnings Call

You May Also Like

HOTH
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure